Meropenem in the treatment of complicated skin and soft tissue infections

References

• Alvarez-LermaFICU-Acquired Pneumonia Study GroupModification of empiric antibiotic treatment in patients with pneumonia acquired in the intensive care unitIntensive Care Med199622387948796388
   PubMed Web of Science ®Google Scholar
• AstraZeneca PharmaceuticalsMYSTIC surveillance study online database [online]2006 Accessed on 21 April 2006. URL: http://www.mystic-data.org/main.htm
   Google Scholar
• BowlerPGDuerdenBIArmstrongDGWound microbiology and associated approaches to wound managementClin Microbiol Rev2001142446911292638
   PubMed Web of Science ®Google Scholar
• BreedtJTerasJGardovskisJSafety and efficacy of tigecycline in treatment of skin and skin structure infections: results of a double-blind phase 3 comparison study with vancomycinaztreonamAntimicrob Agents Chemother20054946586616251309
   PubMed Web of Science ®Google Scholar
• BukharieHAbdelhadiMSaeedIEmergence of methicillin-resistant Staphylococcus aureus as a community pathogenDiagn Microbiol Infect Dis2001401411448556
   PubMed Web of Science ®Google Scholar
• BushKNew–lactamases in gram-negative bacteria: diversity and impact on the selection of antimicrobial therapyClin Infect Dis2001321085911264037
   PubMed Web of Science ®Google Scholar
• CarmeliYTroilletNKarchmerAWHealth and economic outcomes of antibiotic resistance in Pseudomonas aeruginosaArch Intern Med199915911273210335691
   PubMed Web of Science ®Google Scholar
• [CDCP] Centers for Disease Control and PreventionIncidence of soft tissue infections: San Francisco General Hospital – 1996–2000Morbid Mortal Weekly Report2001503814
   PubMedGoogle Scholar
• ChowJWSatishchandranVSnyderTAIn vitro susceptibilities of aerobic and facultative gram-negative bacilli isolated from patients with intra-abdominal infections worldwide: the 2002 Study for Monitoring Antimicrobial Resistance Trends (SMART)Surg Infect2006643947
   Google Scholar
• ColardynFFaulknerKLIntravenous meropenem versus imipenem/cilastatin in the treatment of serious bacterial infections in hospitalized patients. Meropenem Serious Infection Study GroupJ Antimicrob Chemother199638523378889726
   PubMed Web of Science ®Google Scholar
• ColskyASKirsnerRSKerdelFAAnalysis of antibiotic susceptibilities of skin wound flora in hospitalized dermatology patients. The crisis of antibiotic resistance has come to the surfaceArch Dermatol1998134100699722732
   PubMedGoogle Scholar
• CraigWAPharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and menClin Infect Dis1998261109455502
   PubMed Web of Science ®Google Scholar
• DiNubileMJLipskyBAComplicated infections of skin and skin structures: when the infection is more than skin deepJ Antimicrob Chemother200453Suppl S2ii37-ii5015150182
   PubMedGoogle Scholar
• DoernGVJonesRNPfallerMABacterial pathogens isolated from patients with skin and soft tissue infections: frequency of occurrence and antimicrobial susceptibility patterns from the SENTRY Antimicrobial Surveillance ProgramDiagn Microbiol Infect Dis199934657210342110
   PubMed Web of Science ®Google Scholar
• [DPH] US Department of Public Health and Human Services, Public Health ServiceNational Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004Am J Infect Control2004324708515573054
   PubMed Web of Science ®Google Scholar
• EadyEACoveJHStaphylococcal resistance revisited: community-acquired methicillin resistant Staphylococcus aureus – an emerging problem for the management of skin and soft tissue infectionsCurr Opin Infect Dis2003161032412734443
   PubMed Web of Science ®Google Scholar
• EmbilJMIaconisJSotoNComplicated skin and skin structure infections (cSSSI) in diabetic patients: bacteriology and clinical efficacy of meropenem (MEM) and imipenem-cilastatin (IPM) [abstract]Abstracts of the 45th Interscience Conference on Antimicrobial Agents and Chemotherapy200545th Annual Meeting of the American Society for Microbiology16–19 DecemberWashington, DC2306
   Google Scholar
• EronLJLipskyBALowDEManaging skin and soft tissue infections; expert panel recommendations on key decision pointsJ Antimicrob Chemother200352Suppl. S1i3-i1714662806
   PubMedGoogle Scholar
• FabianTCFileTMJrEmbilJMMeropenem versus imipenem-cilastatin for the treatment of hospitalized patients with complicated skin and skin structure infections: results of a multicenter, randomized, double-blind comparative studySurg Infect2005626982
   PubMedGoogle Scholar
• FalagasMEBarefootLGriffithJRisk factors leading to clinical failure in the treatment of intra-abdominal or skin/soft tissue infectionsEur J Clin Microbiol Infect Dis199615913219031873
   PubMed Web of Science ®Google Scholar
• FishDNSingletaryTJMeropenem: a new carbapenem antibioticPharmacother19971764469
   PubMed Web of Science ®Google Scholar
• FridkinSKHagermanJCMorrisonMMethicillin-resistant Staphylococcus aureus disease in three communitiesN Engl J Med200535214364415814879
   PubMed Web of Science ®Google Scholar
• FuchsPCBarryALBrownSDIn vitro activities of ertapenem (MK-0826) against clinical bacterial isolates from 11 North American medical centersAntimicrob Agents Chemother20014519151811353653
   PubMed Web of Science ®Google Scholar
• FungHBChangJYKuczynskiSA practical guide to the treatment of complicated skin and soft tissue infectionsDrugs20036314598012834364
   PubMed Web of Science ®Google Scholar
• GarauJBlanquerJCoboLProspective, randomized, multicentre study of meropenem versus imipenem/cilastatin as empiric monotherapy in severe nosocomial infectionsEur J Clin Microbiol Infect Dis199716789969447899
   PubMed Web of Science ®Google Scholar
• Garnacho-MonteroJGarcia-GarmendiaJLBarrero-AlmodovarAImpact of adequate empiric antibiotic therapy on the outcome of patients admitted to the intensive care unit with sepsisCrit Care Med20033127425114668610
   PubMed Web of Science ®Google Scholar
• GrahamDRLucastiCMalafaiaOErtapenem once daily versus piperacillin-tazobactam 4 times per day for treatment of complicated skin and skin-structure infections in adults: results of a prospective, randomized, double-blind multicenter studyClin Inf Dis20023414608
   PubMed Web of Science ®Google Scholar
• GraysonMLGibbonsGWHabershawGMUse of ampicillin/sulbactam versus imipenem/cilastatin in the treatment of limb-threatening foot infections in diabetic patientsClin Infect Dis199418683938075257
   PubMed Web of Science ®Google Scholar
• HechtDWPrevalence of antibiotic resistance in anaerobic bacteria: worrisome developmentsClin Infect Dis20043992715206059
   PubMed Web of Science ®Google Scholar
• HutchisonMFaulknerKLTurnerPJA compilation of meropenem tissue distribution dataJ Antimicrob Chemother199536Suppl A43568543498
   PubMedGoogle Scholar
• JodráVMPérezCDSolerLSResults of the Spanish national nosocomial infection surveillance network (VICONOS) for surgery patients from January 1997 through December 2003Am J Infect Control2006341344116630977
   PubMed Web of Science ®Google Scholar
• JonesMESchmitzFJFluitACFrequency of occurrence and antimicrobial susceptibility of bacterial pathogens associated with skin and soft tissue infections during 1997 from an international surveillance programEur J Clin Microbiol Infect Dis199918403810442417
   PubMed Web of Science ®Google Scholar
• JonesMEKarlowskyJADraghiDCEpidemiology and antibiotic susceptibility patterns of pathogens isolated from skin and soft tissue infections in the USA and Europe: a guide to appropriate antimicrobial therapyInt J Antimicrob Agents2003224061914522104
   PubMed Web of Science ®Google Scholar
• KarlowskyJADraghiDCJonesMESurveillance for antimicrobial susceptibility among clinical isolates of Pseudomonas aeruginosa and Acinetobacter baumanii from hospitalized patients in the United States, 1998 to 2001Antimicrob Agents Chemother2003471681812709340
   PubMed Web of Science ®Google Scholar
• KollefMHShermanGWardSinadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patientsChest19991154627410027448
   PubMed Web of Science ®Google Scholar
• KutiJLNightingaleCHNicolauDPOptimizing pharmacodynamic target attainment using the MYSTIC antibiogram: data collected in North America in 2002Antimicrob Agents Chemother20044824647015215095
   PubMed Web of Science ®Google Scholar
• LamiJLWilsonSEHopkinsJAAdjunctive antimicrobials in surgery of soft tissue infections: evaluation of cephalosporins and carbapenemsAm Surg199157769741746792
   PubMed Web of Science ®Google Scholar
• LeiboviciLShragaIDruckerMThe benefit of appropriate empirical antibiotic treatment in patients with bloodstream infectionJ Intern Med1998244379869845853
   PubMed Web of Science ®Google Scholar
• LipskyBABerendtARDeeryHGDiagnosis and treatment of diabetic foot infectionsClin Infect Dis20043988591015472838
   PubMed Web of Science ®Google Scholar
• LipskyBAArmstrongDGCitronDMErtapenem versus piperacillin/tazobactam for diabetic foot infections (SIDESTEP): prospective, randomized, controlled, double-blinded, multicentre trialLancet2005366169570316291062
   PubMed Web of Science ®Google Scholar
• LivermoreDMCarterMWBagelSIn vitro activities of ertapenem (MK-0826) against recent clinical bacteria collected in Europe and AustraliaAntimicrob Agents Chemother2001451860711353638
   PubMed Web of Science ®Google Scholar
• LunaCMVujacichPNiedermanMSImpact of BAL data on the therapy and outcome of ventilator-associated pneumoniaChest1997111676859118708
   PubMed Web of Science ®Google Scholar
• MaglioDTengRThyrumPTPharmacokinetic profile of meropenem, administered at 500 milligrams every 8 hours, in plasma and cantharidin-induced skin blister fluidAntimicrob Agents Chemother2003471771312709358
   PubMed Web of Science ®Google Scholar
• MastertonRGKutiJLTurnerPJThe OPTAMA programme: utilizing MYSTIC (2002) to predict critical pharmacodynamic target attainment against nosocomial pathogens in EuropeJ Antimicrob Chemother20055571715574471
   PubMed Web of Science ®Google Scholar
• Merrem (meropenem) product package insert2005 (October). AstraZeneca Pharmaceuticals, Wilmington, Delaware, USA
   Google Scholar
• MoutonJWVan Den AnkerJNMeropenem clinical pharmacokineticsClin Pharmacokinet199528275867648757
   PubMed Web of Science ®Google Scholar
• MutnickAHRhombergPRSaderHSAntimicrobial usage and resistance trend relationships from the MYSTIC programme in North America (1999–2001)J Antimicrob Chemother200453290614711839
   PubMed Web of Science ®Google Scholar
• NeuhauserMMWeinsteinRARydmanRAntibiotic resistance among gram-negative bacilli in US intensive care units. Implications for fluoroquinolone useJAMA2003289885812588273
   PubMed Web of Science ®Google Scholar
• NicholsRLOptimal treatment of complicated skin and skin structure infectionsJ Antimicrob Chemother199944192310511393
   PubMed Web of Science ®Google Scholar
• NicholsRLSmithJWGecklerRWMeropenem versus imipenem/cilastatin in the treatment of hospitalized patients with skin and soft tissue infectionsSouth Med J1995883974047716590
   PubMed Web of Science ®Google Scholar
• NorrbySRGildonKMSafety profile of meropenem: a review of nearly 5,000 patients treated with meropenemScand J Infect Dis19993131010381210
   PubMed Web of Science ®Google Scholar
• OngCTKutiJLNicolauDPPharmacodynamic modeling of imipenem-cilastatin, meropenem, and piperacillin-tazobactam for empiric therapy of skin and soft tissue infections: a report from the OPTAMA programSurg Infect2005641926
   PubMedGoogle Scholar
• PatersonDLMulazimogluLCasellasJMEpidemiology of ciprofloxacin resistance and its relationship to extended-spectrum beta-lactamase production in Klebsiella pneumoniae isolates causing bacteremiaClin Infect Dis200030473810722430
   PubMed Web of Science ®Google Scholar
• PatersonDLKoW-CVon GottbergAAntibiotic therapy for Klebsiella pneumoniae bacteremia: implications of production of extended-spectrum–lactamasesClin Infect Dis20033931715206050
   PubMed Web of Science ®Google Scholar
• PellizzerGStrazzaboscoMPresiSDeep tissue biopsy vs. superficial swab culture monitoring in the microbiological assessment of limb-threatening diabetic foot infectionDiabet Med200118822711678973
   PubMed Web of Science ®Google Scholar
• PfallerMASegretiJOverview of the epidemiological profile and laboratory detection of extended-spectrum–lactamasesClin Infect Dis200642Suppl 4S1536316544266
   PubMed Web of Science ®Google Scholar
• QualeJBratuSGuptaJInterplay of efflux system, ampC, and oprD expression in carbapenem resistance of Pseudomonas aeruginosa clinical isolatesAntimicrob Agents Chemother20065016334116641429
   PubMed Web of Science ®Google Scholar
• RaghavanMLindenPKNewer treatment options for skin and soft tissue infectionsDrugs20046416214215257625
   PubMed Web of Science ®Google Scholar
• Red Book2005Montvale, NJ, USAMedical Economics Company, Inc
   Google Scholar
• RelloJAusinaVRicartMImpact of previous antimicrobial therapy on the etiology and outcome of ventilator-associated pneumoniaChest1993104123058404198
   PubMed Web of Science ®Google Scholar
• RennieRPJonesRNMutnickAHOccurrence and antimicrobial susceptibility patterns of pathogens isolated from skin and soft tissue infections: report from the SENTRY Antimicrobial Surveillance Program (United States and Canada, 2000)Diagn Microbiol Infect Dis2003452879312730001
   PubMed Web of Science ®Google Scholar
• RhombergPRFritscheTRSaderHSComparative antimicrobial potency of meropenem tested against Gram-negative bacilli: report from the MYSTIC Surveillance Program in the United States (2004)J Chemother2005174596916323433
   PubMed Web of Science ®Google Scholar
• SaderHSJonesRNSilvaJBSkin and soft tissue infections in Latin American medical centers: four-year assessment of the pathogen frequency and antimicrobial susceptibility patternsDiagn Microbiol Infect Dis200244281812493176
   PubMed Web of Science ®Google Scholar
• StevensDLBisnoALChambersHFPractice guidelines for the diagnosis and management of skin and soft-tissue infectionsClin Infect Dis200541137340616231249
   PubMed Web of Science ®Google Scholar
• SwartzMNMandellGLBennettJEDolinRCellulitis and subcutaneous tissue infectionsPrinciples and practice of infectious diseases20005th edNew YorkChurchill Livingstone103757
   Google Scholar
• TanJSWishnowRMTalanDATreatment of hospitalized patients with complicated skin and skin structure infections: double-blind, randomized, multicenter study of piperacillin-tazobactam versus ticarcillin-clavulanateAntimicrob Agents Chemother199337158068215266
   PubMed Web of Science ®Google Scholar
• TasslerHCullmannWElhardtDTherapy of soft tissue infections with piperacillin/tazobactamJ Antimicrob Chemother199331Suppl A105128383651
   PubMed Web of Science ®Google Scholar
• TepplerHGesserRMFriedlandIRSafety and tolerability of ertapenemJ Antimicrob Chemother200453Suppl S2ii75ii8115150186
   PubMedGoogle Scholar
• TurnidgeJDThe pharmacodynamics of beta-lactamsClin Infect Dis19982710229675443
   PubMed Web of Science ®Google Scholar
• VinhDCEmbilJMRapidly progressive soft tissue infectionsLancet Infect Dis200555011316048719
   PubMed Web of Science ®Google Scholar
• WilcoxMHEfficacy of tigecycline in complicated skin and skin structure infections and complicated intra-abdominal infectionsJ Chemother200517Suppl 123916285355
   PubMed Web of Science ®Google Scholar
• WilsonMASkin and soft-tissue infections: impact of resistant gram-positive bacteriaAm J Surg2003186Suppl 5A35S-41S
   PubMedGoogle Scholar
• WisemanLRWagstaffAJBrogdenRNMeropenem: a review of its antibacterial activity, pharmacokinetic properties, and clinical efficacyDrugs199550731017588092
   PubMed Web of Science ®Google Scholar
• ZervosMJHershbergerENicolauDPRelationship between fluoroquinolone use and changes in susceptibility to fluoroquinolones of selected pathogens in 10 United States teaching hospitals, 1991–2000Clin Infect Dis2003371643814689346
   PubMed Web of Science ®Google Scholar